• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes.

作者信息

Hyak Jonathan M, Huang Ying, Rogers Kerry A, Bhat Seema A, Grever Michael R, Byrd John C, Kittai Adam S, Jones Dan, Miller Cecelia R, Woyach Jennifer A

机构信息

Department of Medicine and Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.

Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH; and.

出版信息

Blood Adv. 2022 Sep 13;6(17):5124-5127. doi: 10.1182/bloodadvances.2022007708.

DOI:10.1182/bloodadvances.2022007708
PMID:35834733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9631640/
Abstract
摘要

相似文献

1
Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes.在慢性淋巴细胞白血病（CLL）中，联合抑制BCL2和BTK在两类药物单药治疗后均显示出疗效。
Blood Adv. 2022 Sep 13;6(17):5124-5127. doi: 10.1182/bloodadvances.2022007708.
2
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.布鲁顿酪氨酸激酶抑制增加慢性淋巴细胞白血病对BCL-2的依赖性并增强对维奈托克的敏感性。
Leukemia. 2017 Oct;31(10):2075-2084. doi: 10.1038/leu.2017.32. Epub 2017 Jan 23.
3
BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.BCL-2 抑制作为慢性淋巴细胞白血病的治疗方法。
Curr Treat Options Oncol. 2021 Jun 10;22(8):66. doi: 10.1007/s11864-021-00862-z.
4
An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.评价泽布替尼，一种 BTK 抑制剂，用于治疗慢性淋巴细胞白血病。
Expert Rev Hematol. 2020 Oct;13(10):1039-1046. doi: 10.1080/17474086.2020.1817735. Epub 2020 Sep 14.
5
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.慢性淋巴细胞白血病中尼妥珠单抗联合维奈托克的临床前评估。
J Hematol Oncol. 2022 Nov 15;15(1):166. doi: 10.1186/s13045-022-01386-1.
6
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.选择性 BTK 抑制可提高苯达莫司汀治疗反应并使慢性淋巴细胞白血病中的免疫效应功能正常化。
Int J Cancer. 2019 Jun 1;144(11):2762-2773. doi: 10.1002/ijc.32010. Epub 2019 Jan 16.
7
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.药理学和蛋白质分析表明，维奈托克（ABT-199）是慢性淋巴细胞白血病中与伊布替尼联用的最佳搭档。
Clin Cancer Res. 2015 Aug 15;21(16):3705-15. doi: 10.1158/1078-0432.CCR-14-2809. Epub 2015 Mar 31.
8
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).布鲁顿酪氨酸激酶（BTK）的功能对慢性淋巴细胞白血病（CLL）的发展和扩张很重要。
Blood. 2014 Feb 20;123(8):1207-13. doi: 10.1182/blood-2013-07-515361. Epub 2013 Dec 5.
9
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.BTK 抑制剂 ARQ 531 靶向伊布替尼耐药的 CLL 和 Richter 转化。
Cancer Discov. 2018 Oct;8(10):1300-1315. doi: 10.1158/2159-8290.CD-17-1409. Epub 2018 Aug 9.
10
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.靶向Axl抑制使慢性淋巴细胞白血病B细胞易于凋亡，并与BTK抑制剂联合使用时显示出协同/相加效应。
Clin Cancer Res. 2015 May 1;21(9):2115-26. doi: 10.1158/1078-0432.CCR-14-1892. Epub 2015 Feb 11.

引用本文的文献

1
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.双重难治性和双重暴露慢性淋巴细胞白血病患者的特征及预后
Blood Adv. 2025 Jun 10;9(11):2808-2817. doi: 10.1182/bloodadvances.2025016006.
2
Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.BTK抑制剂治疗后慢性淋巴细胞白血病的耐药机制及应对方法
Leuk Lymphoma. 2025 Jul;66(7):1176-1188. doi: 10.1080/10428194.2025.2466101. Epub 2025 Feb 19.
3
BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies.

本文引用的文献

1
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare).在针对 CLL/SLL 的靶向治疗时代识别未满足的需求：“过去的一切都是序幕”（莎士比亚）。
Clin Cancer Res. 2022 Feb 15;28(4):603-608. doi: 10.1158/1078-0432.CCR-21-1237.
2
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.维奈托克联合奥滨尤妥珠单抗治疗后的微小残留病动态：来自随机 CLL14 研究的延长治疗后随访。
J Clin Oncol. 2021 Dec 20;39(36):4049-4060. doi: 10.1200/JCO.21.01181. Epub 2021 Oct 28.
3
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
血液系统恶性肿瘤中的BCL-2抑制剂：预测反应的生物标志物及管理策略
Front Oncol. 2025 Jan 21;14:1501950. doi: 10.3389/fonc.2024.1501950. eCollection 2024.
4
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.慢性淋巴细胞白血病：2025年流行病学、发病机制、诊断与治疗最新进展
Am J Hematol. 2025 Mar;100(3):450-480. doi: 10.1002/ajh.27546. Epub 2025 Jan 28.
5
Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed.2024年慢性淋巴细胞白血病的治疗顺序：我们所处的位置以及前进的方向。
Cancers (Basel). 2024 May 25;16(11):2011. doi: 10.3390/cancers16112011.
6
Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need.双难治性慢性淋巴细胞白血病的治疗——未满足的临床需求。
Int J Mol Sci. 2024 Jan 27;25(3):1589. doi: 10.3390/ijms25031589.
7
A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine.慢性淋巴细胞白血病的肿瘤微环境模型可进行药物敏感性测试以指导精准医疗。
Cell Death Discov. 2023 Apr 13;9(1):125. doi: 10.1038/s41420-023-01426-w.
8
Cellular Therapies in Chronic Lymphocytic Leukemia and Richter's Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant.慢性淋巴细胞白血病和里氏转化中的细胞疗法：嵌合抗原受体T细胞、自然杀伤细胞和异基因干细胞移植的最新进展
Cancers (Basel). 2023 Mar 18;15(6):1838. doi: 10.3390/cancers15061838.
9
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax.对 BTK 抑制剂和 venetoclax 耐药的 CLL 的新型治疗方法和联合治疗。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):316-322. doi: 10.1182/hematology.2022000344.
10
Chronic lymphocytic leukemia treatment algorithm 2022.2022 年慢性淋巴细胞白血病治疗算法
Blood Cancer J. 2022 Nov 29;12(11):161. doi: 10.1038/s41408-022-00756-9.
伊布替尼联合维奈托克用于慢性淋巴细胞白血病的一线治疗：随机、II 期 CAPTIVATE 研究微小残留病灶队列的主要分析结果。
J Clin Oncol. 2021 Dec 1;39(34):3853-3865. doi: 10.1200/JCO.21.00807. Epub 2021 Oct 7.
4
Frontline Management of CLL in 2021.2021年慢性淋巴细胞白血病的一线管理
JCO Oncol Pract. 2022 Feb;18(2):109-113. doi: 10.1200/OP.21.00258. Epub 2021 Jul 21.
5
How I treat chronic lymphocytic leukemia after venetoclax.维奈托克治疗慢性淋巴细胞白血病后的体会
Blood. 2021 Aug 5;138(5):361-369. doi: 10.1182/blood.2020008502.
6
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.奥滨尤妥珠单抗、伊布替尼和维奈克拉联合治疗初治和复发/难治性慢性淋巴细胞白血病的 II 期研究。
J Clin Oncol. 2020 Nov 1;38(31):3626-3637. doi: 10.1200/JCO.20.00491. Epub 2020 Aug 14.
7
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.阿卡替尼联合或不联合奥滨尤妥珠单抗对比苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（ELEVATE TN）：一项随机、对照、III 期临床试验。
Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.
8
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.BTK 抑制剂治疗对 Venetoclax 耐药的 CLL 患者有效。
Blood. 2020 Jun 18;135(25):2266-2270. doi: 10.1182/blood.2020004782.
9
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.评估 Venetoclax 停药后治疗 CLL 的疗效表明 BTK 抑制是一种有效的策略。
Clin Cancer Res. 2020 Jul 15;26(14):3589-3596. doi: 10.1158/1078-0432.CCR-19-3815. Epub 2020 Mar 20.
10
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.RESONATE-2 研究 5 年随访：伊布替尼一线治疗 CLL/SLL 患者的长期疗效和安全性。
Leukemia. 2020 Mar;34(3):787-798. doi: 10.1038/s41375-019-0602-x. Epub 2019 Oct 18.